ADVANCEMENTS IN NOVEL DRUG DELIVERY SYSTEMS FOR PSORIASIS MANAGEMENT: A COMPREHENSIVE REVIEW

Abstract

Psoriasis, a chronic autoimmune skin condition, presents significant challenges in management due to its complex pathology and persistent nature. Traditional systemic and topical treatments often result in limited efficacy and undesirable side effects. Recent advancements in novel drug delivery systems (NDDS) offer promising alternatives by enhancing drug bioavailability, targeting affected tissues, and minimizing adverse effects. This review explores cutting-edge NDDS technologies, including nanocarriers like liposomes, nanoparticles, and niosomes; transdermal systems; and microneedle-based approaches. These strategies improve therapeutic outcomes by optimizing drug release profiles and site-specific delivery. Emphasis is placed on biodegradable polymers, hydrogels, and stimuli-responsive systems that offer controlled release and reduced systemic exposure. The integration of NDDS with biologics, such as monoclonal antibodies and small-molecule inhibitors, also holds potential to revolutionize psoriasis management. Future research directions include clinical validation and addressing scalability challenges for widespread adoption. NDDS represent a paradigm shift in psoriasis therapy, addressing unmet needs and improving patient quality of life.